Core Viewpoint - Tianjin Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the dual targets, blocking the tumor cell cycle and inducing apoptosis in tumor cells [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]

Core Viewpoint - Tianshili (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshili Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi"), has received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the two targets, blocking the tumor cell cycle and inducing tumor cell apoptosis [1] - TSL2109 aims to synergistically kill tumor cells through its dual-target mechanism [1]

Core Viewpoint - Tianshili's subsidiary, Jiangsu Diyi, has received approval from the National Medical Products Administration for clinical trials of TSL2109 capsules for advanced solid tumors [1] Company Summary - Tianshili's full subsidiary Jiangsu Diyi has been granted a clinical trial approval notice for TSL2109 capsules [1]

Core Viewpoint - Tianjin Tianshi Company (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tianshi Diyi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of TSL2109 capsules for advanced solid tumors [1] Group 1 - TSL2109 capsules are a novel dual-target small molecule inhibitor developed in collaboration with China Pharmaceutical University [1] - The drug works by selectively inhibiting downstream signaling pathways of the dual targets, blocking the tumor cell cycle and inducing tumor cell apoptosis [1] - TSL2109 is designed to synergistically kill tumor cells through its dual-target mechanism [1]

证券代码：600535 证券简称：天士力 编号：临 2025-065 号 天士力医药集团股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）全资子公司江苏 天士力帝益药业有限公司（以下简称"江苏帝益"）收到国家药品监督管理局核 准签发关于TSL2109胶囊用于晚期实体瘤的《药物临床试验批准通知书》，现就 相关情况公告如下： 一、药物基本情况 药品名称：TSL2109胶囊 注册分类：化学药品1类 适应症：晚期实体瘤 剂型：胶囊剂 规格：（1）100 mg（2）25 mg 申请人：江苏天士力帝益药业有限公司、中国药科大学 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 07 月 23 日受理的 TSL2109 胶囊临床试验申请符合药品注册的有关要求，同意 本品开展晚期实体瘤的临床试验。 二、药物研发及相关情况 TSL2109 胶囊是由江苏帝益和中国药科大学联合申报的具有全新结构的双靶 点小分子抑制剂 ...

每经AI快讯，9月24日，天士力（600535）(600535.SH)公告称，全资子公司江苏天士力帝益药业有限公 司收到国家药品监督管理局核准签发关于TSL2109胶囊用于晚期实体瘤的《药物临床试验批准通知 书》。TSL2109胶囊是由江苏帝益和中国药科大学联合申报的具有全新结构的双靶点小分子抑制剂，目 前国内外尚无同类双靶点药物进入临床试验阶段。截至公告日，江苏帝益对TSL2109胶囊的累计研发投 入为2462.51万元。根据相关法律法规，药物在获得临床试验通知书后，尚需开展临床试验，然后经国 家药监局审评、审批通过后方可上市生产。新药研发周期长、环节多，未来产品市场竞争形势也将发生 变化，公司将积极推进该项目，并及时履行信息披露义务。 ...

Core Viewpoint - The announcement indicates that Tianjin Tasly Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of TSL2109 capsules, a new dual-target small molecule inhibitor for advanced solid tumors [1] Company Summary - Jiangsu Diyi, a wholly-owned subsidiary of Tianjin Tasly, is responsible for the development of TSL2109 capsules in collaboration with China Pharmaceutical University [1] - The total investment in the research and development of TSL2109 capsules has reached RMB 24.6251 million [1] Industry Summary - The approval for clinical trials highlights the ongoing innovation in the pharmaceutical industry, particularly in the development of new cancer therapies [1] - The development process of new drugs is characterized by uncertainty, and future market competition dynamics are expected to change [1]

对于急性脑梗患者而言，时间就是生命。只有在有效的时间窗内进行溶栓治疗，才能真正避免脑细胞死亡和后遗症。 脑卒中，也就是常见的"中风"，已成为我国成年人致死、致残的首位病因。 "受年龄增长等各种因素影响，人的血管内可能出现斑块，一旦发生斑块破裂或者脱落，将出现中风，要通过神经介入和溶栓等再灌注治疗，尽快把堵住的 血管通开，不然每延迟一分钟，患者大脑中就有190万个神经细胞死亡。"谈及脑卒中这一当下成年人的"头号杀手"，一位三甲医院的医生极为感慨道，大脑 一旦损伤则是不可逆的，所以越早识别中风，抢救的可能性越大，愈后恢复的效果也越好。 突破时间窗，国产创新药展现治疗新希望 中国卒中学会发布的《中国卒中报告2020》统计，我国每年新发脑卒中约340万例，其中缺血性脑卒中（脑梗）占比超过70%，且发病率仍以每年4%-6%的 速度增长。 在此前宣武医院宋海庆教授团队公布的一项关于普佑克的Ⅱa期临床试验中，首次证明了普佑克静脉溶栓治疗对发病后4.5-6h的AIS患者安全有效，患者90d 功能独立率超过60%，且不增加死亡和症状性脑出血（sICH）的风险。 无论是急诊室里的争分夺秒，还是药企研发中的技术攻坚，一场围绕时间、 ...

证券之星消息，9月24日中药板块较上一交易日下跌0.28%，维康药业领跌。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | 4.27% | 21.58万 | | 1.41亿 | | 600129 | 太极集团 | 21.75 | 3.97% | 16.50万 | | 3.54Z | | 603998 | 方盛制药 | 11.83 | 3.23% | 44.30万 | | 5.23亿 | | 300181 | 佐力药业 | 18.09 | 3.02% | 17.62万 | | 3.17亿 | | 000423 | 东阿阿胶 | 48.10 | 2.69% | 10.18万 | | 4.87亿 | | 600329 | 达仁堂 | 45.08 | 2.69% | 7.64万 | | 3.43亿 | | 300534 | ...

Core Viewpoint - The announcement details the progress of guarantees provided by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. for its subsidiary Kunming Pharmaceutical Group, specifically for its wholly-owned subsidiaries [1][3][7] Summary by Sections Guarantee Overview - The total guarantee amount for the subsidiaries is set at 14 million RMB, with a cumulative guarantee balance of 39.8 million RMB already provided [1][2] - The guarantee is within the previously estimated limits and does not involve any counter-guarantees [2] Guarantee Progress - The guarantees are aimed at supporting the operational and business development needs of Kunming Pharmaceutical Group's subsidiaries [4] - The guarantee plan was approved during the board meeting and the annual shareholders' meeting [3] Company Information - The guaranteed companies, Xishuangbanna Dai Medicine and Dali Huirui Pharmaceutical, have a good credit status and are not listed as dishonest executors [5] Guarantee Agreement Details - The guarantee period lasts for three years from the date of the agreement [6] - Other shareholders of Dali Huirui have signed a maximum guarantee contract, with individual shareholders assuming joint guarantee responsibilities [6] Necessity and Reasonableness of Guarantee - The guarantees are deemed necessary to meet the production and operational needs of Kunming Pharmaceutical Group for 2025, enhancing financing efficiency and reducing costs [6] - The company maintains oversight of the financial status and cash flow of the guaranteed subsidiaries, ensuring manageable risk [6] Cumulative Guarantee Amounts - As of the announcement date, the total external guarantee balance for Kunming Pharmaceutical Group and its subsidiaries is 122.2 million RMB, representing 2.33% of the latest audited net assets [6] - The total guarantee limit for 2025 for Kunming Pharmaceutical Group and Tian Shi Li Pharmaceutical Group is 1.35615 billion RMB, accounting for 6.81% of the latest audited net assets [7]